Overview

Low Dose Naltrexone (LDN) Immune Monitoring

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
University of Alabama at Birmingham
Collaborator:
Stanford University
Treatments:
Naltrexone